NCT05875311 Telemonitoring System for Improving Continuity of Care in Patients With Chronic Coronary Syndrome (TELSINCORC)
| NCT ID | NCT05875311 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Catcronic Salut SL |
| Condition | Chronic Coronary Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2023-11-28 |
| Primary Completion | 2024-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2023-11-28 with a primary completion date of 2024-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In a randomized clinical trial, a comprehensive telerehabilitation system with a prolonged follow-up strategy demonstrated superiority over a control group with centre-based cardiac rehabilitation in terms of physical activity, VO2 max, adherence to a Mediterranean diet, lipid particle profile and cost-effectiveness. The aim of this study is to demonstrate an extension of the benefit to patients with chronic coronary syndrome in primary care.
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Patients after more than one year of an acute coronary syndrome of both sexes. * Age equal to or less than 72 years. Exclusion Criteria: * Refusal of informed consent * Advanced biological age. * Kidney failure (GFR \< 30ml/min/1.73 m2). * Liver failure (GOT \>2 times normal value). * Ejection fraction less than 50%. * Uncontrolled blood pressure (\>140/90 mmHg). * Uncontrolled heart failure. * Dissecting aortic aneurysm. * Uncontrolled ventricular tachycardia or other dangerous ventricular arrhythmias. * Aortic or mitral valve disease. * Recent systemic or pulmonary embolism. * Active or recent thrombophlebitis. * Acute infectious diseases. * Uncontrolled supraventricular arrhythmias or tachycardia. * Repeated or frequent ventricular ectopic activity. * Moderate pulmonary hypertension. * Ventricular aneurysm. * Uncontrolled diabetes, thyrotoxicosis, myxedema, * Conduction disorders such as: complete atrioventricular block. Left bundle branch block. * Wolf-Parkinson-White syndrome. * Fixed rate pacing. * Severe anaemia. * Psychoneurotic disorders. * Neuromuscular, musculoskeletal and arthritic disorders that may limit activity. may limit activity.
Contact & Investigator
Ernesto Dalli Peydró, MD
PRINCIPAL INVESTIGATOR
Hospital Arnau de VIlanova. Valencia
Frequently Asked Questions
Who can join the NCT05875311 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 72 Years, studying Chronic Coronary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05875311 currently recruiting?
Yes, NCT05875311 is actively recruiting participants. Contact the research team at ernestodallip@gmail.com for enrollment information.
Where is the NCT05875311 trial being conducted?
This trial is being conducted at Valencia, Spain.
Who is sponsoring the NCT05875311 clinical trial?
NCT05875311 is sponsored by Catcronic Salut SL. The principal investigator is Ernesto Dalli Peydró, MD at Hospital Arnau de VIlanova. Valencia. The trial plans to enroll 160 participants.